Regenicin Inc (RGIN) 0.0465 $RGIN FDA Grants Or
Post# of 273242
Posted On: 09/19/2016 7:13:18 AM
Regenicin Inc (RGIN) 0.0465 $RGIN
FDA Grants Orphan-Drug Designation for Regenicin's NovaDerm® Cultured Skin Substitute
PR Newswire - Mon Aug 29, 12:24PM CDT
Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation status to the company's NovaDerm® cultured skin substitute. The Company believes NovaDerm to be the only autologous cultured skin substitute prepared from the patient's own skin cells consisting of both epidermal and dermal layers previously designated by the FDA as a biologic for treatment of patients with deep-partial or full-thickness thermal burns greater than or equal to 30% total body surface area. The FDA has granted orphan-drug designation status to NovaDerm for treatment of burns requiring skin grafting.
Market Maker Surveillance Report. KND, INTC, MDR, CDNS, HTZ, RGIN, Highest Net Buy Volume With Lowest Price Friction For Thursday, November 20th 2014
M2 - Fri Nov 21, 3:16AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4485 companies with "abnormal" market making, 2789 companies with positive Friction Factors and 2000 companies with negative Friction Factors. Here is a list of the top companies with the highest net buy volume on Thursday and lowest price Friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. KINDRED HEALTHCARE, INC. (NYSE:KND), INTEL CORPORATION (NASDAQ:INTC), McDermott International Inc (NYSE:MDR), CADENCE DESIGN SYSTEMS, INC. (NASDAQ:CDNS), HERTZ GLOBAL HOLDINGS, INC. (NYSE:HTZ), Regenicin Inc (OTC:RGIN). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
KND: 9.91 (+0.11), MDR: 4.80 (-0.08), HTZ: 49.22 (+1.18), CDNS: 24.23 (-0.60), INTC: 37.67 (+1.11)
Regenicin Enters Into Asset Purchase Agreement with Amarantus Bioscience Holdings, Inc.
PR Newswire - Wed Nov 19, 11:46AM CST
Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs, announced today that it has entered into an Asset Purchase Agreement with Amarantus Bioscience Holdings, Inc. ("Amarantus"
. Under the agreement, Amarantus acquires Regenicin rights and claims in the company's litigation currently pending against Lonza Walkersville and Lonza America, Inc. This included all of Regenicin's Cutanagen intellectual property rights and any Lonza manufacturing know-how technology Regenicin may have. In addition, Regencin will sell to Amarantus its PermaDerm trademark and related intellectual property rights associated with it.
Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza
Thomson Reuters ONE - Mon Nov 17, 3:20PM CST
- Engineered Skin substitute (ESS): Phase 1/ Early Phase 2 product candidate that has potential to be a revolutionary new treatment for severe burns
FDA Grants Orphan-Drug Designation for Regenicin's NovaDerm® Cultured Skin Substitute
PR Newswire - Mon Aug 29, 12:24PM CDT
Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation status to the company's NovaDerm® cultured skin substitute. The Company believes NovaDerm to be the only autologous cultured skin substitute prepared from the patient's own skin cells consisting of both epidermal and dermal layers previously designated by the FDA as a biologic for treatment of patients with deep-partial or full-thickness thermal burns greater than or equal to 30% total body surface area. The FDA has granted orphan-drug designation status to NovaDerm for treatment of burns requiring skin grafting.
Market Maker Surveillance Report. KND, INTC, MDR, CDNS, HTZ, RGIN, Highest Net Buy Volume With Lowest Price Friction For Thursday, November 20th 2014
M2 - Fri Nov 21, 3:16AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4485 companies with "abnormal" market making, 2789 companies with positive Friction Factors and 2000 companies with negative Friction Factors. Here is a list of the top companies with the highest net buy volume on Thursday and lowest price Friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. KINDRED HEALTHCARE, INC. (NYSE:KND), INTEL CORPORATION (NASDAQ:INTC), McDermott International Inc (NYSE:MDR), CADENCE DESIGN SYSTEMS, INC. (NASDAQ:CDNS), HERTZ GLOBAL HOLDINGS, INC. (NYSE:HTZ), Regenicin Inc (OTC:RGIN). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
KND: 9.91 (+0.11), MDR: 4.80 (-0.08), HTZ: 49.22 (+1.18), CDNS: 24.23 (-0.60), INTC: 37.67 (+1.11)
Regenicin Enters Into Asset Purchase Agreement with Amarantus Bioscience Holdings, Inc.
PR Newswire - Wed Nov 19, 11:46AM CST
Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs, announced today that it has entered into an Asset Purchase Agreement with Amarantus Bioscience Holdings, Inc. ("Amarantus"
. Under the agreement, Amarantus acquires Regenicin rights and claims in the company's litigation currently pending against Lonza Walkersville and Lonza America, Inc. This included all of Regenicin's Cutanagen intellectual property rights and any Lonza manufacturing know-how technology Regenicin may have. In addition, Regencin will sell to Amarantus its PermaDerm trademark and related intellectual property rights associated with it. Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza
Thomson Reuters ONE - Mon Nov 17, 3:20PM CST
- Engineered Skin substitute (ESS): Phase 1/ Early Phase 2 product candidate that has potential to be a revolutionary new treatment for severe burns
(0)
(0)Scroll down for more posts ▼